IPHA: Innate Pharma reports €96.8M cash and nine-month revenue of €3.4M
Cash €96.8M at Sep 30, 2026, runway to end-Q1 2028; 9M revenue €3.4M vs €2.3M; Phase 1 IPH4502 data Nov 18, PACIFIC-9 readout H1 2027.
What this filing says
Innate Pharma filed its third quarter 2026 business and financial update, reporting cash and financial assets of €96.8 million as of September 30, 2026, with an anticipated cash horizon until the end of Q1 2028. The update reiterates timelines for its Nectin-4 ADC IPH4502 data, the lacutamab Phase 3 trial start, and the AstraZeneca-led PACIFIC-9 readout, which is now expected in the first half of 2027.
Key figures
- Cash and financial assets
- €96.8 million
- Nine-month revenue 2026
- €3.4 million
- Nine-month revenue 2025
- €2.3 million
- Financial liabilities
- €16.2 million
- Remaining ATM balance
- $75 million
- Private placement gross proceeds
- €30 million
Positive for shareholders
- Cash position was strengthened by the $75 million Sobi upfront payment and the August 2026 private placement.
- Cash is expected to last until the end of Q1 2028, according to the update.
- Nine-month revenue rose from €2.3 million to €3.4 million year over year.
Negative for shareholders
- The August 2026 private placement of ordinary shares adds new shares, which can dilute existing holders.
- The PACIFIC-9 readout has been pushed to the first half of 2027, a later timeline for a trial that includes monalizumab.
- Financial liabilities of €16.2 million remain on the balance sheet.
Written by Quantisnow AI from this filing. Not financial advice.
Form 6-K main document
Key terms
- ADC:
- Antibody-drug conjugate, a therapy that attaches a cancer-killing drug to an antibody that targets tumor cells.
- At-The-Market program:
- An arrangement that lets a company sell new shares into the open market over time at prevailing prices.
- Accelerated approval:
- An FDA pathway that allows earlier approval of a drug for a serious condition based on an interim result, with confirmation required later.
- Dose-escalation:
- An early trial design that gradually increases the dose given to patients to assess safety and tolerability.
FAQ
How much cash does Innate Pharma have and how long will it last?
Innate Pharma reported cash, cash equivalents and financial assets of €96.8 million as of September 30, 2026, with an anticipated cash horizon until the end of Q1 2028.
When is the PACIFIC-9 readout now expected?
The AstraZeneca-led PACIFIC-9 Phase 3 readout is now expected in the first half of 2027.
When does Innate Pharma plan to file with the FDA for lacutamab?
The company plans an FDA filing in H2 2027 for accelerated approval in Sézary syndrome, once the confirmatory Phase 3 study is underway.
Historical context for IPHA
Across the 26 sessions after earlier IPHA headlines, the stock closed higher 11 times and lower 15 times, with a median move of 3.1% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | IPHA | SPY |
|---|---|---|---|
| Nov 5, 2026 | Innate Pharma Reports Third Quarter 2026 Business and Financial Update | -1.8% | -4.4% |
| Oct 27, 2026 | Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 | +1.4% | +0.6% |
| Oct 21, 2026 | Innate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare Conference | -0.5% | +0.5% |
| Oct 20, 2026 | Innate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial Update | +8.1% | +0.3% |
| Sep 17, 2026 | Innate Pharma Reports First Half 2026 Business Update and Financial Resultsand 1 other headline that session | -5.0% | +1.1% |
| Sep 10, 2026 | Innate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business Update | -3.6% | -0.6% |
Keep researching IPHA
- What is Form 6-K?The SEC form foreign private issuers use to furnish material information they publish at home, such as earnings releases and major announcements.
- Form 8-K explainedWhat a Form 8-K is, when it is due, and what each key item number means, from 1.01 material agreements and 2.02 earnings to 4.02 restatements and 5.02 executive changes.
- IPHA earnings historyPast Innate Pharma S.A. ADS earnings releases, newest first.
- IPHA financial statementsRevenue, profit, cash flow and balance sheet from Innate Pharma S.A. ADS's SEC filings.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Listed since
- 2019
Follow IPHA and get a push notification the moment its next story breaks.